MTOR and lung carcinoma: Conversely, other studies showed reduced PD‐L1 levels with PI3K, mTORC1 or mTORC1/2 inhibitors in lung cancer cells [51] that were associated with mTOR inactivation or AMP‐activated protein kinase (AMPK) activation, both sensors of the nutrient and energy status of the cell.